TuHURA Biosciences, Inc. (NASDAQ: HURA) entered into an at‑the‑market (ATM) common‑stock offering agreement for up to $50 million on April 8, 2026, with H.C. Wainwright & Co., LLC serving as the sales agent. The agreement allows the company to sell shares directly to the public as market conditions permit, providing a flexible source of capital to support its clinical development pipeline and general corporate purposes.
The ATM agreement itself was signed on November 3, 2025. Under the terms, the company may sell shares at an illustrative price of $1.79 per share, potentially issuing up to 27,932,960 shares. The offering is designed to extend the company’s runway while acknowledging that the sale of additional shares will dilute existing shareholders.
TuHURA’s cash position at the end of 2025 was $3.6 million, and the company reported net cash outflows from operating activities of $27.7 million for the year. The ATM offering is therefore a critical financing tool to bridge the gap between the company’s high cash burn and the capital required to advance its Phase 3 Merkel cell carcinoma trial and other programs.
The company’s pipeline includes the Phase 3 accelerated‑approval trial of IFx‑2.0 in advanced or metastatic Merkel cell carcinoma, with enrollment expected to conclude in mid‑2027. In addition, TuHURA has expanded its portfolio through the acquisition of Kineta, Inc. on June 30, 2025, adding the VISTA‑inhibiting antibody TBS‑2025 and antibody‑drug conjugate programs to its development slate.
Dr. James Bianco, President and CEO, said the company is moving all programs forward and that the Phase 3 trial is on track to complete enrollment in mid‑2027. He emphasized the importance of securing sufficient capital to sustain the company’s clinical development trajectory.
Investor sentiment has been mixed, with some analysts maintaining buy ratings while others have downgraded the stock to sell. The market reaction has been tempered by concerns over the company’s high cash burn, the need for additional financing, and the potential dilution from the ATM offering.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.